ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)
CAPS Rating:
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.
Recs
This biotech has been "promising" for two decades but its platform seems finally at a critical mass with several drugs poised ( in collaboration with larger, pharma companies ) to enter the market, especially in areas not well-served by other drugs. Intrinsically, the platform should entail fewer side effects than more traditional drugs.